UnfoldIPThemes

Company patents

NIPPON SHINYAKU CO., LTD.

NIPPON SHINYAKU CO., LTD. appears to be shifting its focus within pharmaceutical innovation, with a notable decline in its core 'Therapeutic Activity (Pharma)' patents, which represent 44.1% of its portfolio and have seen a -50.0% YoY drop so far in 2026. This contrasts with a fluctuating but significant interest in 'Heterocyclic Compounds (Pharma)', which experienced a remarkable +400.0% YoY growth in 2025 before a sharp decline in 2026, suggesting an agile but potentially less stable R&D pipeline in this area.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

59 US filings (since 2023) · 6 categories · 9 themes

Nucleic Acid-Based Therapies

Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.

Therapeutic Activity (Pharma)Pharmaceutical Preparations
Who else files here? →
28since 2023
-20.0%YoY
Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Pharmaceutical PreparationsHeterocyclic Compounds (Pharma)
Who else files here? →
13since 2023
-20.0%YoY
Drug Candidate Synthesis

Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.

General Organic Chemistry Methods
Who else files here? →
8since 2023
+200.0%YoY
API Solid Form Engineeringfiltered

Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.

Heterocyclic Compounds (Pharma)General Organic Chemistry Methods
Who else files here? →
6since 2023
0.0%YoY
Integrated Dispensing Mechanisms

Containers or packaging components featuring active mechanisms for controlled release, preparation, or delivery of their contents, such as liquids, bulk materials, volatile compounds, or single-serve portions.

Containers & Packaging
Who else files here? →
4since 2023
0.0%YoY
Recombinant Protein & Peptide Therapeutics

Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.

Therapeutic Activity (Pharma)
Who else files here? →
2since 2023
new
Immune Checkpoint Modulation

Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.

Therapeutic Activity (Pharma)
Who else files here? →
1since 2023
n/a
Advanced Cell & Gene Therapies

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Pharmaceutical Preparations
Who else files here? →
1since 2023
n/a
Microbiome & Susceptibility Profiling

Techniques for identifying microorganisms, assessing their viability, quantifying their presence, profiling their metabolic activity, or determining their susceptibility to antimicrobial agents, often in complex biological or environmental samples.

Genetic & Microbiological Assays
Who else files here? →
1since 2023
n/a

Patents

Showing 1-9 of 9

API Solid Form Engineering
Page 1 of 1
US 20250034098 A1APPLICATION
C07D241/20

CRYSTALLINE SUBSTITUTED PYRAZINES AS PGI2 RECEPTOR AGONISTS

Filed:2024-10-17Pub:2025-01-30
Applicant:NIPPON SHINYAKU CO., LTD.

A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2θ) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å). A form-II crystal of Compound B, which shows peaks at diffraction angles (2θ) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å).

US 12152009 B2GRANTED
C07D241/26

Crystalline substituted pyrazines as PGI2 receptor agonists

Filed:2023-04-12Pub:2024-11-26
Applicant:NIPPON SHINYAKU CO., LTD.

A main object of the present invention is to provide a novel crystal of 2-{4-[N-{5, 6-diphenylpyrazin-2-yl}-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2θ) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å). A form-II crystal of Compound B, which shows peaks at diffraction angles (2θ) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å).

US 20230303500 A1APPLICATION
C07D241/20

CRYSTALLINE SUBSTITUTED PYRAZINES AS PGI2 RECEPTOR AGONISTS

Filed:2023-04-12Pub:2023-09-28
Applicant:NIPPON SHINYAKU CO., LTD.

A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5, 6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2θ) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å) . A form-II crystal of Compound B, which shows peaks at diffraction angles (2θ) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å) .

US 20230250083 A1APPLICATION
C07D401/14

CRYSTALS

Filed:2023-04-13Pub:2023-08-10
Applicant:NIPPON SHINYAKU CO., LTD.

A main object of the present invention is to provide new crystals of (S)-N 2 -[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine maleate (hereinafter, referred to as “compound A”). A Form-I crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 6.9 degrees, 9.4 degrees, 12.5 degrees, 15.1 degrees, 16.4 degrees, 18.3 degrees, 19.0 degrees, 24.9 degrees, 25.4 degrees, 27.3 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu Kα radiation (λ=1.54 Å). A Form-II crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 6.9 degrees, 9.2 degrees, 12.4 degrees, 14.8 degrees, 16.5 degrees, 18.1 degrees, 18.5 degrees, 19.8 degrees, 23.6 degrees, 24.9 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu Kα radiation (λ=1.54 Å).

US 11680055 B2GRANTED
C07D401/14

Crystals

Filed:2018-09-27Pub:2023-06-20
Applicant:NIPPON SHINYAKU CO., LTD.

A main object of the present invention is to provide new crystals of (S)-N 2 -[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N 6 -(pyrazin-2-yl)pyridine-2,6-diamine maleate (hereinafter, referred to as “compound A”). A Form-I crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 6.9 degrees, 9.4 degrees, 12.5 degrees, 15.1 degrees, 16.4 degrees, 18.3 degrees, 19.0 degrees, 24.9 degrees, 25.4 degrees, 27.3 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu Kα radiation (λ=1.54 Å). A Form-II crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 6.9 degrees, 9.2 degrees, 12.4 degrees, 14.8 degrees, 16.5 degrees, 18.1 degrees, 18.5 degrees, 19.8 degrees, 23.6 degrees, 24.9 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu Kα radiation (λ=1.54 Å).

US 11655218 B2GRANTED
C07D241/26

Crystalline substituted pyrazines as PGI2 receptor agonists

Filed:2020-12-28Pub:2023-05-23
Applicant:NIPPON SHINYAKU CO., LTD.

A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2θ) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å). A form-II crystal of Compound B, which shows peaks at diffraction angles (2θ) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å).

US 20220281830 A1APPLICATION
C07D241/20

SALT

Filed:2020-08-19Pub:2022-09-08
Applicant:NIPPON SHINYAKU CO., LTD.

The present invention relates to a novel salt of 2-(4-(5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid (hereinafter referred to as “Compound B”) and a crystal of the salt thereof.

US 20210114995 A1APPLICATION
C07D241/20

CRYSTALLINE SUBSTITUTED PYRAZINES AS PGI2 RECEPTOR AGONISTS

Filed:2020-12-28Pub:2021-04-22
Applicant:NIPPON SHINYAKU CO., LTD.

A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2θ) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å). A form-II crystal of Compound B, which shows peaks at diffraction angles (2θ) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å).

US 10906879 B2GRANTED
C07D241/26

Crystalline substituted pyrazines as PGI2 receptor agonists

Filed:2018-09-27Pub:2021-02-02
Applicant:NIPPON SHINYAKU CO., LTD.

A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2θ) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å). A form-III crystal of Compound B, which shows peaks at diffraction angles (2θ) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å).

1